Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Daniel O'Day reports proposed sales of GILD common stock under Form 144. The filing lists recent transactions including a sale of $17,346,000.00 for 115,640 shares on 02/05/2026, and earlier sales of 115,640 shares on 01/23/2026 for $15,611,400.00. The record also shows multiple 10,000-share transactions in late 2025 and January 2026 with corresponding proceeds listed.
Gilead Sciences is a large biopharmaceutical company focused on HIV, liver disease, COVID-19 and oncology, with a global presence in more than 35 countries. Its medicines include HIV regimens like Biktarvy and Descovy, liver treatments such as Epclusa and Vemlidy, COVID-19 therapy Veklury, and cell therapies Yescarta and Tecartus.
The company highlights a broad late‑stage pipeline in virology and oncology, including lenacapavir for HIV prevention, bulevirtide for hepatitis delta, and multiple CAR T and antibody‑drug conjugate programs. It emphasizes extensive patent protection, with key products such as Biktarvy and Veklury covered into the 2030s, and notes growing pricing and reimbursement pressures from U.S. policy changes like the Inflation Reduction Act, Medicaid and 340B rules, and international cost controls.
Gilead also describes significant manufacturing infrastructure in the U.S., Europe and Canada, reliance on contract manufacturers, and a workforce of about 17,000 employees. It stresses human capital, ESG priorities and detailed risk factors spanning competition, product demand volatility, regulatory change, climate rules and complex U.S. drug‑pricing reforms.
Gilead Sciences plans to acquire Arcellx through a tender offer for $115.00 per share in cash plus a $5.00 contingent value right (CVR) per share, implying equity value of $7.8 billion. Each CVR pays $5.00 in cash if cumulative worldwide sales of anitocabtagene autoleucel (anito-cel) reach $6.0 billion by December 31, 2029.
A Gilead subsidiary will launch a tender offer for all Arcellx shares it does not already own, needing more than 50% of outstanding shares, with customary antitrust and other closing conditions. Gilead currently owns about 11.5% of Arcellx, and support agreements cover an additional 10.3% of shares.
Following successful completion of the offer, Arcellx will merge into the Gilead subsidiary, and remaining shares will receive the same cash and CVR consideration. Anito-cel’s Biologic License Application for fourth-line relapsed or refractory multiple myeloma has been accepted by the FDA, with a Prescription Drug User Fee Act action date of December 23, 2026, and Gilead expects the deal to be accretive to earnings per share in 2028 and beyond upon FDA approval.
Gilead Sciences executive Johanna Mercier reported a mix of option exercises and stock sales. On February 17, 2026, she exercised 25,000 non-qualified stock options, acquiring 25,000 shares of common stock at $66.64 per share through a derivative exercise.
That same day, she sold 18,405 shares at $154.182, 9,395 shares at $154.9105, and 200 shares at $155.62 in open-market transactions under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she held 120,288 shares of common stock and 48,110 options directly.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock in an open-market transaction. The sale took place on February 17, 2026, at an average price of $154.43 per share. After this sale, he directly owned 167,779 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024, and the share balance also reflects purchases through the company’s Employee Stock Purchase Plan.
A person named Johanna Mercier has filed to sell up to 28,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $4,324,227.70, on or about 02/17/2026 on the NASDAQ market.
The shares to be sold include 25,000 shares acquired via a stock option exercise for cash on 02/17/2026 and 3,000 restricted shares acquired on 03/10/2024. Over the prior three months, Mercier sold 3,000 shares on 01/15/2026 for $372,930.00 and another 3,000 shares on 12/15/2025 for $366,000.00.
GILD insider Andrew Dickinson has filed a Form 144 to potentially sell 3,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney on NASDAQ around February 17, 2026, with an indicated aggregate market value of $463,290.
The 3,000 shares were acquired as performance shares from the issuer on January 24, 2023. Over the past three months, Dickinson has already sold 3,000 common shares on December 15, 2025 for $366,000 and another 3,000 shares on January 15, 2026 for $372,930.
Gilead Sciences executive Keeley M. Cain Wettan, EVP Gen Counsel, Legal & Comp, filed an initial ownership report showing direct holdings in Gilead Sciences, Inc. common stock and equity awards as of February 4, 2026. The filing lists 3,944 shares of common stock, restricted stock units covering 5,440 and 11,342 shares, and several non-qualified stock options with exercise prices from $57.92 to $117.21 and expirations between 2032 and 2035. The restricted stock units and options vest over three- or four-year schedules, with portions vesting on the first anniversary of grant and the remainder vesting quarterly or annually until fully vested.
Gilead Sciences filed a Form 13F Holdings Report disclosing its institutional holdings. The filing lists 6 reported holdings with a combined market value of $1,935,507,854. The report was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, on 02-12-2026.
Gilead Sciences reported higher fourth quarter and full-year 2025 results, driven mainly by its HIV and liver disease portfolios. Q4 2025 revenue rose 5% to $7.9 billion, and diluted EPS increased to $1.74. Full-year 2025 revenue grew 2% to $29.4 billion, with diluted EPS jumping to $6.78 from $0.38, helped by lower IPR&D charges, higher product sales and lower SG&A.
Product sales excluding Veklury increased 4% to $28.0 billion in 2025. HIV sales grew 6% to $20.8 billion, including Biktarvy up 7% to $14.3 billion and Descovy up 31% to $2.8 billion. Liver disease sales rose 6% to $3.2 billion, while Veklury declined 49% to $911 million as COVID-19 hospitalizations fell.
Non-GAAP diluted EPS for 2025 was $8.15, up from $4.62, reflecting strong underlying profitability. Gilead generated $10.0 billion in operating cash flow during 2025, maintained product gross margin near 78% on a GAAP basis and 86% on a non-GAAP basis, and ended the year with $10.6 billion in cash, cash equivalents and marketable debt securities.
For full-year 2026, Gilead projects product sales of $29.6–$30.0 billion, including Veklury of $600 million, and diluted EPS of $6.75–$7.15, with non-GAAP diluted EPS of $8.45–$8.85. The company highlighted continued launches such as Yeztugo for HIV prevention and Livdelzi for liver disease, as well as planned oncology and HIV pipeline launches.